Ann: March 2023 Quarterly Update and Appendix 4C, page-19

First 19 Last

Share
Profile

Follow
DerrickJ

411 Posts.

113

01/05/23

20:59

Post #: 67552249
Share

Originally posted by cashisking: ↑

2023 for Prescient is unquestionably going to be very exciting.

Ed Schoonveld
About

Experienced leader, author, consultant and coach in biopharmaceutical pricing, value and access related fields.

Areas of expertise

- determining optimal global, regional and local drug pricing strategies to secure patient access while supporting ongoing business needs

- drug development and commercial decision making to improve commercial potential

- executive training and coaching for drug industry leaders in the area of global pricing and market access

- expert witness in drug pricing related cases

Author of "The Price of Global Health" (Routledge Publishing, 3rd edition), Pharmaceutical Commerce columnist.

Its quite obvious that a commercial deal is near.

Prescient is pleased to announce that it has appointed global pricing expert Mr Ed Schoonveld as advisor for global commercial, pricing and access.

Mr Schoonveld will assist Prescient in guiding its commercial strategy for PTX-100 in particular as the program matures to incorporate considerations pertaining to commercial opportunities for various indications, competitive landscapes, label claims, patient access for various lines of therapy and potential pricing considerations.

Mr Schoonveld is a global authority on pricing and health economics having authored the definitive reference book on global pricing and market access that has been used widely in the pharmaceutical industry for over a decade. Mr Schoonveld has advised leading global pharmaceutical companies including Wyeth, Eli Lilly and BMS on market access strategies, global pricing policies, clinical trial designs and internal organisational and process challenges.

Adding a professional of Mr Schoonveld’s calibre and experience to the Prescient team comes at a very important time for the Company as a crucial inflexion point for PTX-100 draws closer, and the
Company must now make strategic decisions normally reserved for pharmaceutical companies and commercial stage biotechs.

Whilst the nature of biotechnology drug development necessarily focusses on scientific and clinical aspects, Prescient must now sharpen its focus on other strategic inputs, including commercial considerations, pricing and patient access. This is crucial in planning for success, and Mr Schoonveld’s experience and insights in guiding other drugs to commercial success will be very valuable indeed.

Expand

I wonder if his expertise in the field is going to be called upon for Cellpryme as it’s nearing its first deal?

PTX Price at posting: 9.8¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

First 19 Last

(20min delay)
Last 4.2¢		Change 0.001(2.44%)		Mkt cap ! $33.01M

Open	High	Low	Value	Volume
4.0¢	4.2¢	4.0¢	$33.72K	821.2K

Buyers (Bids)

No.	Vol.	Price($)
1	339	4.1¢

Sellers (Offers)

Price($)	Vol.	No.
4.2¢	22994	2

View Market Depth

No.	Vol.	Price($)
1	339	0.041
6	761836	0.040
7	638470	0.039
4	635000	0.038
2	67000	0.037

Price($)	Vol.	No.
0.042	22994	2
0.043	125082	2
0.044	100000	1
0.045	300000	1
0.046	201669	3

Last trade - 14.02pm 18/06/2024 (20 minute delay)


Last 4.2¢		Change 0.001 ( 2.44 %)
Open	High	Low	Volume
4.0¢	4.2¢	4.0¢	182233
Last updated 14.02pm 18/06/2024 ?

PTX (ASX) Chart

Ann: March 2023 Quarterly Update and Appendix 4C, page-19

Featured News

Recharge returns to fire ravaged James Bay for fieldwork

White Cliff confirms large and continuous gold system underneath resource at Reedy's in WA

From the Floor question: "How can we make gold mining shares become valued again?"

From the Floor question: "Why are you going back to Ned's Creek for a drilling campaign?" | Lodestar Minerals

ASX Market Update: RBA holds rates at 4.35% in line with consensus | 18 June 2024

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: March 2023 Quarterly Update and Appendix 4C, page-19

Featured News

Top Stories

Recharge returns to fire ravaged James Bay for fieldwork

White Cliff confirms large and continuous gold system underneath resource at Reedy's in WA

From the Floor question: "How can we make gold mining shares become valued again?"

From the Floor question: "Why are you going back to Ned's Creek for a drilling campaign?" | Lodestar Minerals

ASX Market Update: RBA holds rates at 4.35% in line with consensus | 18 June 2024

Buyers (Bids)

Sellers (Offers)

Featured News